Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence

Neuropsychopharmacology

Volumn 41, Issue 4, 2016, Pages 1179-1187

  Boileau, Isabelle ^a,b   McCluskey, Tina ^a   Tong, Junchao ^a,b   Furukawa, Yoshiaki ^a   Houle, Sylvain ^a,b   Kish, Stephen J ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DIHYDROTETRABENAZINE; DOPAMINE; LEVODOPA; METHAMPHETAMINE; VESICULAR MONOAMINE TRANSPORTER; CARBON; TETRABENAZINE;

ABSTINENCE; ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; DRUG BINDING; DRUG USE; FEMALE; HUMAN; IMAGING; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WITHDRAWAL SYNDROME; AMPHETAMINE DEPENDENCE; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; DRUG EFFECTS; METABOLISM; SYNAPSE VESICLE; YOUNG ADULT;

ADULT; AMPHETAMINE-RELATED DISORDERS; CARBON RADIOISOTOPES; COCAINE; COGNITION DISORDERS; CORPUS STRIATUM; DOPAMINE; FEMALE; HUMANS; MALE; METHAMPHETAMINE; POSITRON-EMISSION TOMOGRAPHY; SYNAPTIC VESICLES; TETRABENAZINE; YOUNG ADULT;

EID: 84957824532     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.267     Document Type: Article

References (46)

1. Boileau I, Houle S, Rusjan PM, Furukawa Y, Wilkins D, Tong J et al (2010). Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans. Synapse 64: 417-420.
2. Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P et al (2008). Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker? J Neurosci 28: 9850-9856.
3. 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J Nucl Med 40: 283-289.
4. de La Fuente-Fernandez R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB et al (2003). VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse 49: 20-28.
5. de la Fuente-Fernandez R, Sossi V, McCormick S, Schulzer M, Ruth TJ, Stoessl AJ (2009). Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse 63: 713-716.
6. Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF (1997). Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imag 16: 145-158.
7. Ehringer H, Hornykiewicz O (1960). Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menches und ihr verhalten bei erkrankungen des extrapyramiden systems. Klin Wochenschr 38: 1236-1239.
8. First MB, Spitzer RL, Gibbon M, Williams JBW (1995). Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. (SCID/NP) New York: Biometrics Research, New York State Psychiatric Institute, November 2002.
9. Frey KA, Koeppe RA, Kilbourn MR (2001). Imaging the vesicular monoamine transporter. Adv Neurol 86: 237-247.
10. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S et al (1996). Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 40: 873-884.
11. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997). Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6: 279-287.
12. Hornykiewicz O (2001). Dopamine and Parkinson's disease. A personal view of the past, the present, and the future. Adv Neurol 86: 1-11.
13. Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J et al (2006). Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology 185: 327-338.
14. Kalasinsky KS, Hugel J, Kish SJ (2004). Use of MDA (the 'love drug') and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J Forensic Sci 49: 1106-1112.
15. Kaye S, Darke S (2002). Determining a diagnostic cut-off on the Severity of Dependence Scale (SDS) for cocaine dependence. Addiction 97: 727-731.
16. 11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. Nucl Med Biol 37: 3-8.
17. Kish SJ (2008). Pharmacologic mechanisms of crystal meth. Cmaj 178: 1679-1682.
18. Kish SJ (2014). Chapter 08: The Pathology of Methamphetamine Use in the Human Brain From: The Effects of Drug Abuse on the Human Nervous System, edited by Bertha Madras and Michael Kuhar. Elsevier: Amsterdam, The Netherlands.
19. Kitamura O, Tokunaga I, Gotohda T, Kubo S (2007). Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users. Int J Legal Med 121: 163-168.
20. 11C] dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab 16: 1288-1299.
21. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4(Part 1): 153-158.
22. Lees AJ, Tolosa E, Olanow CW (2014). Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov Disord 30: 19-36.
23. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y et al (2003). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamineinduced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23: 285-300.
24. McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J et al (2008). Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 62: 91-100.
25. 11C] WIN-35,428. J Neurosci 18: 8417-8422.
26. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM (2005). The nature, time course and severity of methamphetamine withdrawal. Addiction 100: 1320-1329.
27. Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ et al (2004). Why is parkinsonism not a feature of human methamphetamine users? Brain 127(Part 2): 363.
28. Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J et al (2011). Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 134(Pt 11): 3290-3298.
29. Narendran R, Lopresti BJ, Martinez D, Mason NS, Himes M, May MA et al (2012). In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. Am J Psychiatry 169: 55-63.
30. Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB (2006). Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 319: 237-246.
31. Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F et al (2006). An automated method for the extraction of regional data from PET images. Psychiatry Res 147: 79-89.
32. Seiden LS, Ricaurte GA (1987). Neurotoxicity of Methamphetamine and Related Drugs. Raven: New York, NY.
33. Taylor AE, Saint-Cyr JA (1995). The neuropsychology of Parkinson's disease. Brain Cogn 28: 281-296.
34. Thomas DM, Francescutti-Verbeem DM, Kuhn DM (2009). Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity. J Neurochem 109: 1745-1755.
35. Tong J, Boileau I, Furukawa Y, Chang LJ, Wilson AA, Houle S et al (2011). Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab 31: 2065-2075.
36. Tong J, Fitzmaurice P, Furukawa Y, Schmunk GA, Wickham DJ, Ang LC et al (2014). Is brain gliosis a characteristic of chronic methamphetamine use in the human? Neurobiol Dis 67: 107-118.
37. 11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse 62: 873-876.
38. Topp L, Mattick RP (1997). Validation of the amphetamine dependence syndrome and the SAmDQ. Addiction 92: 151-162.
39. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K (1995). The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294: 577-583.
40. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M et al (2001a). Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21: 9414-9418.
41. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D et al (2001b). Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377-382.
42. Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D et al (2012). Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 17: 918-925.
43. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM et al (1996a). Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2: 699-703.
44. Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F et al (1996b). Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 40: 428-439.
45. Wilson JM, Levey AI, Rajput A, Ang L, Guttman M, Shannak K et al (1996c). Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47: 718-726.
46. Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G et al (2010). Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction 105: 1809-1818.